Aktis Oncology, Inc. (AKTS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$27.05+1.50%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating losses near $22.7M and net losses near $18.3M in early 2026: Operating margin -854.0% vs target -22.7M loss; Net margin -713.5% vs target -18.3M loss.
Aktis plans to start Phase 1b cancer trials in late 2026. It expects early trial data in 2027. The company keeps costs steady despite losses. New science leaders joined to improve research.
Aktis lost $18 million in early 2026 and still has no profit. Revenue is small and growth is uncertain. Clinical trials may not succeed or bring sales soon.
The price is about 21% below our fair value near $35. The market expects continued losses and slow growth. We see potential if trials progress as planned.
Breaks if: Losses grow materially beyond 2026-Q1 levels without revenue growth
Manage cash and expenses to support clinical programs with sufficient funding through 2029.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a long-term thesis focused on a healthcare company with ongoing clinical trials. The current state reflects a mix of stable management priorities and moderate risks, with recent performance showing some improvement.
The market currently prices in a justified valuation with a low expectations gap. There is no significant fragility in the stock, suggesting that investors are not overly concerned about immediate risks.
Fundamentals are likely to remain stable as management continues to prioritize clinical trials and maintain financial discipline. However, there is a moderate risk of earnings misses, given the company's history in a high-miss-rate industry.
The thesis hinges on the performance of sector bellwethers and the company's ability to advance its clinical trials without cutting guidance. Additionally, broader economic indicators, such as job reports, could impact sentiment and performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. Cash and equivalents were $538.5M in 2026-Q1 and $517.3M in 2026-Q2, with management expecting funding to last into 2029. Despite net losses, the company is maintaining financial discipline consistent with its stated funding horizon.
“Cash, cash equivalents, and marketable securities as of June 30, 2026, expected to fund operating plan into 2029.”
“Cash, cash equivalents and marketable securities as of March 31, 2026 are expected to fund operations into 2029.”
Breaks if: Trial initiation delayed beyond 2026-Q3 or no data by 2027-Q1
Progress clinical development of AKY-1189 and AKY-2519 through multiple Phase 1b trials targeting various solid tumors, with data expected in 2027.
Stated as a priority in 2 of last 2 quarters. Management initiated Phase 1b trial of AKY-2519 in mCRPC in 2026-Q1 and plans to start a Phase 1b basket trial in other B7-H3 tumors in H2 2026, with preliminary data expected in 2027. The clinical development trajectory is delivering as planned.
“On track to initiate Phase 1b trial of AKY-2519 in other B7-H3 expressing solid tumors in second half of 2026.”
“Initiated Phase 1b clinical trial of AKY-2519 in mCRPC; expect preliminary data in 2027.”
Breaks if: Loss of key science leaders or committee disbandment
Enhance board expertise by appointing experienced leaders to support clinical and corporate milestones.
Newly stated in 2026-Q2. The appointment of Dr. Glenn Gormley to the Board and as co-chair of the Science and Technology Committee was announced in April 2026 to strengthen scientific leadership. This is a one-time governance enhancement with no direct financial metrics but supports the company's clinical and corporate progress.
Over the next 1 to 3 years, AKTS's performance will depend on its clinical progress and the healthcare sector's momentum. Not investment advice.